Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.

Citation data:

Pediatric rheumatology online journal, ISSN: 1546-0096, Vol: 15, Issue: 1, Page: 50

Publication Year:
Usage 94
Abstract Views 56
Full Text Views 37
Link-outs 1
Captures 32
Readers 27
Exports-Saves 5
Mentions 1
News Mentions 1
Social Media 14
Shares, Likes & Comments 12
Tweets 2
Citations 7
Citation Indexes 7
C. H. Spencer; K. Rouster-Stevens; H. Gewanter; G. Syverson; R. Modica; K. Schmidt; H. Emery; C. Wallace; S. Grevich; K. Nanda; Y. D. Zhao; S. Shenoi; S. Tarvin; S. Hong; C. Lindsley; J. E. Weiss; M. Passo; K. Ede; A. Brown; K. Ardalan; W. Bernal; S. Kim; M. L. Stoll; B. Lang; A. M. Huber; R. Carrasco; C. Agaiar; L. Feller; H. Bukulmez; R. Vehe; H. Kim; H. Schmeling; D. Gerstbacher; M. Hoeltzel; B. Eberhard; R. Sundel; A. Patwardhan; Leslie Abramson; Dania Basodan; Johanna Chang; Megan Curran; Kyla Driest; Polly Ferguson; Daniel Horton; Kristin Houghton; Maria Ibarra; Esra Meidan; Marc Natter; Miriam Parsa; Reshma Patel; Sarah Ringold; Tova Ronis; Ken Schikler; Bacha Shaham; Elizabeth Stringer; Hemalatha Srinivasahu; Cagri Toruner; Mary Toth; Dawn Wahezi Show More Hide
Springer Nature
Most Recent Tweet View All Tweets
Most Recent News Mention
article description
The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960's with the use of corticosteroid and immunosuppressive therapy. Yet there remain a minority of children who have refractory disease. Since 2003 the sporadic use of biologics (genetically-engineered proteins that usually are derived from human genes) for inflammatory myositis has been reported. In 2011-2016 we investigated our collective experience of biologics in JDM through the Childhood Arthritis and Rheumatology Research Alliance (CARRA).